ABio Materials, a Korean startup developing exosome-based ingredients and injectables, has raised 10 billion in a Series C round, the company said, signaling investor confidence in a sector that has remained active even amid choppy capital markets. ABio said it has received 7.5 billion so far and expects an additional 4.0 billion; participants included A Ventures, Donghoon Investment and Capstone Partners, with IMM Investment and IBK Securities purchasing secondary shares.
The financing, framed by the company as more than a cash infusion, comes as exosome and “skin-booster” treatments gain traction globally. Citing industry analyses, ABio points to projections that the exosome market could expand from about $250.8 million in 2022 to $3.2 billion by 2032 (a roughly 29.9% compound annual growth rate), while the skin-booster category could approach $2.7 billion by 2030.
Technology and IP
ABio’s pitch to investors centers on two proprietary platforms: ExoTraction®, an extraction and purification process for exosomes, and LNP-DS (Lipid Nano Particle–Delivery System), designed to stabilize and deliver actives. The company says it can develop and commercialize exosomes derived from multiple sources—stem cells, plants and probiotics—claiming scalability beyond a single input type.
A differentiator, ABio says, is its focus on plant-derived exosomes. The firm reports it has isolated exosomes from more than 40 botanicals, including centella and ginseng, emphasizing sustainability, supply security and safety. To support raw-material consistency, ABio operates a smart-farm hydroponic facility. The company lists more than 40 patents and two consecutive “Excellent Patent Award” honors, credentials it argues help de-risk manufacturing and partnering.
Products and Pipeline
ABio’s flagship Celexo brand is built around centella (“cica”) exosomes and is marketed for anti-inflammatory effects, pore appearance, and redness mitigation. Building on that franchise, the company plans a “Celexo Series” over the next year, including skin-booster candidates derived from stem cells, lactobacillus and plant-origin PDRN. Over the following two years, ABio says it aims to add seven skin- and hair-booster products, positioning itself as a specialized global supplier ahead of a planned listing.
Financials and Manufacturing
ABio says its revenue mix is roughly 20% raw materials and 80% finished products. The company reported $6.14M in revenue and $0.79M in operating profit in 2023, increasing revenue to $9.64M in 2024. For 2025, management is targeting $17.86M in revenue and $5.00–$7.14M in operating profit.
To scale production, ABio has acquired a dedicated plant in Cheonan for stem-cell conditioned media and finished goods, a move it expects will improve yields and margins.
Listing Plan and Global Expansion
Backed by the new funding, ABio is preparing a KOSDAQ listing as early as next year. Internationally, the company has established a China subsidiary and is targeting 70% overseas sales, with a longer-term plan to evolve from biocosmetics into bio-healthcare. Using its exosome and LNP-DS platforms, ABio says it is exploring pipelines in skin regeneration, anti-inflammatory care, atopic dermatitis and hair loss, alongside joint research with universities and medical institutes to enable entry into clinical and medical-aesthetics channels.
The Bottom Line
ABio’s Series C underscores investor appetite for scalable exosome manufacturing and delivery. Much now hinges on execution: converting platform claims into reproducible data, meeting regulatory requirements across markets, and proving that the company’s manufacturing build-out can sustain both quality and margin as it pushes from beauty into medical-aesthetics use cases.
Copyright ⓒ 센머니 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
